Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity: A pharmacovigilance case report

Pharmacopsychiatry

Volumn 39, Issue 4, 2006, Pages 150-152

  Stephan, P L ^a   Sirot, E Jaquenoud ^a   Mueller, B ^a   Eap, C B ^b   Baumann, P ^b  

^a Psychiatrische Dienste Aargau AG   (Switzerland)

^b Hopital de Cery   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GAMMA GLUTAMYLTRANSFERASE; KETOCONAZOLE; LIVER ENZYME; MIDAZOLAM; MIRTAZAPINE; NORCLOMIPRAMINE; PROTEIN INHIBITOR; QUETIAPINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; DELUSION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENZYME DEFICIENCY; FOLLOW UP; GENOTYPE; GRAPEFRUIT JUICE; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; LABORATORY TEST; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SLEEP DEPRIVATION; SWEATING; TACHYCARDIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; CHOLELITHIASIS; CLOMIPRAMINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; HUMANS; LIVER; MALE; MIDDLE AGED; PHENOTYPE;

EID: 33746874423     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-946705     Document Type: Article

References (17)

1. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M et al. The AGNP-TDM expert group concensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 1-23
3. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005; 66(Suppl3): 12-19
4. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine - An atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522
5. Eap CB, Buclin T, Cucchia G, Zullino D, Mustert E, Bleiber G et al. Oral administration of a low dose of midazolam (75 micrograms) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004; 60: 237-246
6. Eap CB, Buclin T, Mustert E, Bleiber G, Powell Golay K, Aubert AC et al. Pharmacokinetics of midazolam in CYP3A4 and CYP3A5 genotyped subjects. Eur J Clin Pharmacol 2004; 60: 231-236
7. Glue P, Andersen KO, Hansen MA, Stage KB, Hansen H, Norrie B et al. Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999; 66: 152-165
8. Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004; 37 (Suppl l): S4S11
9. Haller-Gloor F, Eap CB, Turgeon J, Baumann P. High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. Int J Psych Clin Pract 2004; 8: 191-195
10. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004; 26: 486-491
11. Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003; 36 (Suppl 3): S235-243
12. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005; 6: 357-371
13. Nielsen KK, Brøsen K, Hansen MGJ, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation poly morphisms. Clin Pharmacol Ther 1994; 55: 518-527
14. Nielsen KK, Flinois JP, Beaune P, Brosen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277: 1659-1664
15. Sachse C, Haertter S, Mueller MJ, Dragicevic A, Hiemke C. Therapeutisches Drug Monitoring von Quetiapin. Psychopharmakotherapie 2003; 10: 19-22
16. Shimoda K, Jerling M, Böttiger Y, Yasuda S, Morita S, Bertilsson L. Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 1999; 19: 393-400
17. Yokono A, Morita S, Someya T, Hirokane G, Okawa M, Shimoda K. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 2001; 21: 549-555